ASP3291

Telsar Pharma Inc. · Phase 2 active Small molecule

At a glance

Generic name	ASP3291
Sponsor	Telsar Pharma Inc.
Modality	Small molecule
Phase	Phase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Safety, Efficacy, and Tolerability Study of ASP3291 in Patients With Active Ulcerative Colitis (PHASE2)
A Study of a Single Dose of ASP3291 in Subjects With Ulcerative Colitis (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

ASP3291 CI brief — competitive landscape report
ASP3291 updates RSS · CI watch RSS
Telsar Pharma Inc. portfolio CI